Remove Biosimilars Remove Diabetes Remove Pharmaceutical Companies
article thumbnail

STAT+: Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

STAT

Pharmaceutical companies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. The first therapy that delays the onset of type 1 diabetes received approval from the U.S.

Diabetes 246
article thumbnail

Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil

Express Pharma

Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at their production facility in Nova Lima.

Diabetes 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Pharmaceutical Technology

Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

article thumbnail

Biocon signs commercialisation pact with Juno Pharma in Canada for Liraglutide

Express Pharma

Biocon has signed a partnership agreement with Juno Pharmaceuticals, a specialty pharmaceutical company in Canada, for the commercialisation of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.

Diabetes 103
article thumbnail

Insights+ Key Biosimilars Events of May 2023

PharmaShots

Our team at PharmaShots has summarized 16 key events of the biosimilar space of May 2023 1. based on change from baseline on a standardized DAS28-CRP which evaluates the severity of RA using clinical and laboratory data Additionally, the company initiates PK study for AVT05 in Jan 2023. 84% vs 64%) & 2yr. (60%

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes. The post Is India capable of ensuring equitable access to biopharmaceuticals?

article thumbnail

Pharma industry headwinds in remission: ICRA

Express Pharma

The overall credit profile of Indian pharmaceutical companies is expected to remain healthy, supported by their stable earnings profile, comfortable leverage and coverage metrics, and strong liquidity position. Of this, biosimilars will comprise around $35-40 billion.